Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

NCT04915183 is registered in ClinicalTrials.gov with National Institute on Deafness and Other Communication Disorders (NIDCD) as lead sponsor.

NCT NCT04915183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04915183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Phase
Phase 2
Overall status
Recruiting
Start date
July 10, 2024
Completion date
August 31, 2030
Enrollment
224 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, hearing loss